Citadel Advisors
MRKR icon

Citadel Advisors’s Marker Therapeutics MRKR Stock Holding History

Citadel Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.8K Buy
+32,517
New +$47.4K ﹤0.01% 13135
2026
Q1 		– Sell
-58,847
Closed -$87.7K – 13752
2025
Q4 		$87.7K Buy
+58,847
New +$66.6K ﹤0.01% 11738
2024
Q4 		– Sell
-13,032
Closed -$36.8K – 15069
2024
Q3 		$36.8K Buy
+13,032
New +$51.5K ﹤0.01% 12241
2022
Q3 		– Sell
-14,432
Closed -$48K – 13240
2022
Q2 		$48K Buy
+14,432
New +$48K ﹤0.01% 11962
2022
Q1 		– Sell
-1,651
Closed -$9.44K – 14221
2021
Q4 		$16K Sell
1,651
-616
-27% -$8.18K ﹤0.01% 13619
2021
Q3 		$38K Sell
2,267
-27,036
-92% -$554K ﹤0.01% 13488
2021
Q2 		$817K Buy
29,303
+11,132
+61% +$293K ﹤0.01% 8893
2021
Q1 		$407K Buy
18,171
+13,517
+290% +$309K ﹤0.01% 10139
2020
Q4 		$67K Sell
4,654
-220
-5% -$3.42K ﹤0.01% 10445
2020
Q3 		$73K Buy
4,874
+106
+2% +$1.93K ﹤0.01% 9442
2020
Q2 		$99K Sell
4,768
-1,612
-25% -$35.3K ﹤0.01% 8998
2020
Q1 		$121K Buy
+6,380
New +$163K ﹤0.01% 8485
2019
Q4 		– Sell
-8,761
Closed -$448K – 9504
2019
Q3 		$448K Buy
+8,761
New +$518K ﹤0.01% 6936

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Citadel Advisors's MRKR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Marker Therapeutics (MRKR) in Q2 2026: 32,517 shares worth $47.8K. The stake represents ﹤0.01% of the portfolio and ranks #13135 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in MRKR as recently as Q4 2025.

Citadel Advisors first reported a position in MRKR in Q3 2019 and has held it in 13 quarters since. The position peaked at $817K in Q2 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Citadel Advisors held 32,517 shares of Marker Therapeutics worth $47.8K as of Q2 2026.
  • Marker Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Marker Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13135 holding.
  • Citadel Advisors first reported a position in Marker Therapeutics in Q3 2019 and has held it in 13 quarters since.
  • Citadel Advisors's Marker Therapeutics position peaked at $817K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.